ASH 2021: Novel Therapy in Acute Lymphocytic Leukemia
Expert perspectives on clinical data readouts in acute lymphocytic leukemia from the ASH 2021 annual meeting.
Data from the following clinical trials are discussed:
- 1233: Updated results from a phase I study of hyper-CVAD with sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia
- 1231: Superior overall survival with blinatumomab versus chemotherapy as pre-transplant consolidation treatment in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL): longer follow-up (FU) of a phase 3 randomized controlled trial (RCT)
- 4028: Successful outpatient administration of blinatumomab infusion in pediatric patients with acute lymphoblastic leukemia
- 516: Isatuximab in combination with chemotherapy in pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia (ISAKIDS): interim analysis
- 428: Real-world outcomes for pediatric and young adult patients with relapsed refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel: update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
Supported in part by Takeda Oncology. Content developed independently by Onclive®.
Related Videos
Related Content
